News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
755,132 Results
Type
Article (50907)
Company Profile (343)
Press Release (703882)
Multimedia
Podcasts (105)
Webinars (13)
Section
Business (218586)
Career Advice (2578)
Deals (37745)
Drug Delivery (120)
Drug Development (85640)
Employer Resources (183)
FDA (17107)
Job Trends (16258)
News (369413)
Policy (35520)
Tag
Academia (2884)
Accelerated approval (5)
Adcomms (26)
Allergies (93)
Alliances (54219)
ALS (103)
Alzheimer's disease (1480)
Antibody-drug conjugate (ADC) (156)
Approvals (17080)
Artificial intelligence (300)
Autoimmune disease (28)
Automation (16)
Bankruptcy (385)
Best Places to Work (12316)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (222)
Bladder cancer (84)
Brain cancer (30)
Breast cancer (307)
Cancer (2428)
Cardiovascular disease (199)
Career advice (2159)
Career pathing (34)
CAR-T (168)
Cell therapy (470)
Cervical cancer (20)
Clinical research (69495)
Collaboration (928)
Company closure (2)
Compensation (567)
Complete response letters (27)
COVID-19 (2817)
CRISPR (50)
C-suite (265)
Cystic fibrosis (108)
Data (2342)
Decentralized trials (2)
Denatured (39)
Depression (55)
Diabetes (290)
Diagnostics (6740)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (46)
Drug discovery (129)
Drug pricing (127)
Drug shortages (31)
Duchenne muscular dystrophy (101)
Earnings (90914)
Editorial (44)
Employer branding (22)
Employer resources (158)
Events (122243)
Executive appointments (776)
FDA (18513)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (810)
Gene editing (124)
Generative AI (27)
Gene therapy (349)
GLP-1 (822)
Government (4890)
Grass and pollen (5)
Guidances (150)
Healthcare (20195)
Huntington's disease (25)
IgA nephropathy (30)
Immunology and inflammation (144)
Indications (30)
Infectious disease (2977)
Inflammatory bowel disease (154)
Inflation Reduction Act (11)
Influenza (56)
Intellectual property (102)
Interviews (448)
IPO (17195)
IRA (51)
Job creations (4376)
Job search strategy (1823)
Kidney cancer (10)
Labor market (43)
Layoffs (540)
Leadership (23)
Legal (8793)
Liver cancer (80)
Lung cancer (337)
Lymphoma (160)
Machine learning (9)
Management (63)
Manufacturing (360)
MASH (80)
Medical device (14088)
Medtech (14093)
Mergers & acquisitions (21111)
Metabolic disorders (780)
Multiple sclerosis (84)
NASH (21)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2085)
NextGen: Class of 2025 (7150)
Non-profit (4912)
Now hiring (40)
Obesity (420)
Opinion (259)
Ovarian cancer (83)
Pain (105)
Pancreatic cancer (90)
Parkinson's disease (163)
Partnered (24)
Patents (253)
Patient recruitment (119)
Peanut (50)
People (61352)
Pharmaceutical (99)
Pharmacy benefit managers (22)
Phase I (21598)
Phase II (30531)
Phase III (22922)
Pipeline (1385)
Policy (171)
Postmarket research (2757)
Preclinical (9245)
Press Release (69)
Prostate cancer (109)
Psychedelics (35)
Radiopharmaceuticals (262)
Rare diseases (428)
Real estate (6643)
Recruiting (69)
Regulatory (24126)
Reports (48)
Research institute (2568)
Resumes & cover letters (416)
Rett syndrome (5)
RNA editing (5)
RSV (49)
Schizophrenia (81)
Series A (142)
Series B (93)
Service/supplier (13)
Sickle cell disease (57)
Special edition (18)
Spinal muscular atrophy (158)
Sponsored (33)
Startups (3975)
State (2)
Stomach cancer (15)
Supply chain (73)
Tariffs (52)
The Weekly (64)
Vaccines (801)
Venture capitalists (44)
Weight loss (290)
Women's health (39)
Worklife (20)
Date
Last 7 days (971)
Last 30 days (3070)
Last 365 days (33964)
2025 (12298)
2024 (36970)
2023 (41919)
2022 (53287)
2021 (57910)
2020 (56652)
2019 (49910)
2018 (37838)
2017 (34746)
2016 (34737)
2015 (40811)
2014 (34506)
2013 (29574)
2012 (31619)
2011 (32254)
2010 (30144)
Location
Africa (906)
Alabama (59)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (43390)
Australia (7082)
California (6533)
Canada (2095)
China (560)
Colorado (282)
Connecticut (291)
Delaware (163)
Europe (96091)
Florida (965)
Georgia (217)
Idaho (62)
Illinois (595)
India (28)
Indiana (334)
Iowa (11)
Japan (176)
Kansas (109)
Kentucky (27)
Louisiana (12)
Maine (70)
Maryland (959)
Massachusetts (4963)
Michigan (239)
Minnesota (418)
Mississippi (2)
Missouri (90)
Montana (30)
Nebraska (26)
Nevada (68)
New Hampshire (67)
New Jersey (1844)
New Mexico (30)
New York (1850)
North Carolina (1095)
North Dakota (9)
Northern California (2855)
Ohio (218)
Oklahoma (15)
Oregon (40)
Pennsylvania (1442)
Puerto Rico (14)
Rhode Island (33)
South America (1300)
South Carolina (26)
South Dakota (1)
Southern California (2455)
Tennessee (108)
Texas (971)
United States (24854)
Utah (196)
Virginia (167)
Washington D.C. (67)
Washington State (590)
West Virginia (3)
Wisconsin (69)
755,132 Results for "par pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.
April 22, 2024
·
5 min read
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.
March 12, 2024
·
4 min read
Press Releases
Universe Pharmaceuticals INC Announces Share Consolidation
March 20, 2025
·
3 min read
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
April 21, 2025
·
4 min read
Press Releases
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
May 8, 2025
·
5 min read
Press Releases
Nika Pharmaceuticals, Inc. (NIKA) Latest Developments
April 14, 2025
·
2 min read
Press Releases
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025
·
3 min read
Press Releases
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025
May 7, 2025
·
5 min read
Press Releases
ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
May 1, 2025
·
7 min read
Press Releases
CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE
May 6, 2025
·
9 min read
1 of 75,514
Next
